Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2008 Earnings Results

Alnylam Pharmaceuticals Misses on EPS, Stock Up 0.78%

Alnylam Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still saw a slight increase of 0.78%, possibly due to broader market trends or investor sentiment. The lack of revenue data and guidance may leave investors uncertain about the company's near-term performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.31	N/A	-244.44%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing their commitment to long-term objectives. They did not provide specific guidance for future quarters.

Management did not provide specific guidance for future performance.

The company is focused on its long-term strategic goals despite the current results.

Alnylam Pharmaceuticals Misses on EPS, Stock Up 0.78%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Misses on EPS, Stock Up 0.78%

Key numbers

Management commentary